Skip to main content

Table 3 Results of publications of full economics evaluations for liver metastases from colorectal cancer (lmCRC)

From: Economic evaluations of radioembolization with yttrium-90 microspheres in liver metastases of colorectal cancer: a systematic review

Author, year publication (year cost)

Comparators

Costs

Health Outcomes

Ratio cost / Outcome’s health

Original cost

Adjusted to $US PPP [21]

LYG

QALY

ICER

ICUR

ICER

$US PPP/LYG

ICUR

$US PPP /QALY

WTP

Y-90 TARE vs. BSC

        

Bester, 2013 [23]

(2012)

Y-90 TARE

£ 35,487

39,221

2.09

1.50

Y-90 TARE vs. BSC

Y-90 TARE vs. BSC

Y-90 TARE vs. BSC

Y-90 TARE vs. BSC

BSC

£ 12,730

14,069

0.97

0.69

£ 20,323

£ 28,216

22,461

31,185

Difference Δ

Δ £ 22,757

Δ 25,151

Δ 1.12

Δ 0.81

WTP (£30,000/QALY): 57%

 

Cosimelli, 2013 [24]

(2012)a

Y-90 TARE

€ 39,973

41,099

2.12

1.52

Y-90 TARE vs. BSC

Y-90 TARE vs. BSC

Y-90 TARE vs. BSC

Y-90 TARE vs. BSC

BSC

€ 15,347

15,779

0.98

0.70

ND

€ 29,850

ND

30,691

Difference Δ

Δ € 24,626

Δ 25,320

Δ 1.35

Δ 0.83

WTP (€50,000/QALY): 57%

 

Pennington, 2015 [25]

(2013)a

Y-90 TARE

£ 35,487

38,592

2.09

1.50

Y-90 TARE vs. BSC

Y-90 TARE vs. BSC

Y-90 TARE vs. BSC

Y-90 TARE vs. BSC

BSC

£ 12,730

13,844

0.97

0.69

£ 20,323

£ 28,216

22,101

30,684

Difference Δ

Δ £ 22,757

Δ 24,748

Δ 1.12

Δ 0.81

WTP (£30,000/QALY): 57%

 

Brennan, 2020 [26]

(2019)

Y-90 TARE

£ 34,168

34,810

ND

1.50

Y-90 TARE vs. BSC

Y-90 TARE vs. BSC

Y-90 TARE vs. BSC

Y-90 TARE vs. BSC

BSC

£ 15,268

15,268

ND

0.69

£ 18,900

£ 23,435

19,255

23,875

Difference Δ

Δ £ 18,900

Δ 19,255

Δ ND

Δ 0.81

WTP (£30,000/QALY): 56%

 

Y-90 TARE vs. HAI

        

Loveman, 2014 [27]

(2012)

Y-90 TARE + HAI

£ 18,955

20,949

1.86

1.41

Y-90 TARE + HAI vs. HAI

Y-90 TARE + HAI vs. HAI

Y-90 TARE + HAI vs. HAI

Y-90 TARE + HAI vs. HAI

HAI

£ 6,010

6,642

1.49

1.06

£ 35,225

£ 37,303

38,931

41,228

Difference Δ

Δ £ 12,945

Δ 14,307

Δ 0.37

Δ 0.35

WTP (£30,000/QALY): 26%

 
  1. BSC: best supportive care (include chemotherapy, biological agents, and further interventional procedures), HAI: hepatic artery infusion with floxuridine, ICER: cost-effectiveness incremental ratio, ICUR: incremental cost-utility ratio, lmCRC: liver metastases from colorectal cancer, LYG: life years gained, ND: no data, OS: overall survival, QALY: quality-adjusted life years, Y-90 TARE: transarterial radioembolization with yttrium 90, WTP: willingness-to-pay, $US PPP: Purchasing-power-parity exchange rates for the year 2020
  2. a. In case of unspecified cost year, an estimation of proposed cost reference source was used: years 2012 and 2013 were adopted for Cosimelli et al.. and Pennington et al.. respectively